Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories


Imara implements IPO
Pfizer and Lundbeck scored exits as blood-disease therapy developer Imara raised $75.2m, floating at the foot of its range.
Passage Bio amasses $248m for IPO close
The genetic therapy developer, which had raised $126m in funding from investors including Eli Lilly and Access Industries, added $32.4m to the offering.
Revolution hits public markets in $238m IPO
The precision cancer therapy developer, which counts Sanofi as a significant shareholder, floated at the top of an upsized range and saw its price continue to rise post-IPO.
Beam Therapeutics brings IPO to $207m close
The genomic drug developer, which counts GV as an investor, has completed its initial public offering, boosting its size from $180m to $207m.
Schrödinger shuts IPO at $232m
Drug and materials development software provider Schrödinger has capped a successful initial public offering at more than $232m.
Schrödinger shakes out $202m from IPO
The GV and Wuxi AppTec-backed drug development software producer floated above its range and saw its shares rise 68% on their first day of trading.
Beam Therapeutics shines in $180m IPO
Alphabet, Editas and Bio Palette-backed genomic medicine developer Beam will raise $180m in an upsized initial public offering three years after being spun out of Harvard University.
Casper catches $100m in initial public offering
The Target-backed mattress and bedding brand is floating at the bottom of its range, at a valuation of less than half that of its last funding round.

Other News

One Medical wanders onto public markets with $245m
The GV-backed primary care membership service floated at the bottom of its range but garnered a valution of more than $1.7bn.
UCloud stars in $284m IPO
Bertelsmann achieved an exit as the cloud services provider raised $284m in an initial public offering that reportedly valued it at about $2bn.
Danke Apartment deploys IPO
The Bertelsmann, UCommune and Ant Financial-backed property manager raised nearly $130m depite downsizing its initial public offering.
I-Mab enters public markets in $104m IPO
The Tasly and Genexine-backed drug developer floated above the mid-point of its range, in an initial public offering that could end up topping $119m.
Lizhi lists in $45m IPO
The Xiaomi-backed, China-headquartered podcast app developer priced its shares at the bottom of their range to raise $45.1m in a US offering.
OneConnect upgrades IPO to $347m
Ping An's financial technology spinoff, which also counts SoftBank Vision Fund and SBI as shareholders, has sold an additional $35.2m in shares in the offering.

Editor's Picks fills up with $216m IPO
Financial automation software producer Bill is floating above its range as Fleetcor, Mastercard, Amex and a host of banks all scored exits.
Peloton pulls itself to billion-dollar IPO
Comcast NBCUniversal and Grace Beauty scored exits as Peloton Interactive floated at the top of its range to raise $1.16bn, getting a further $100m in a private placement.
Cloudflare clocks up $525m in IPO
Alphabet, Baidu, Microsoft and Qualcomm all notched up exits as the cloud services provider floated above a range that had already been increased.
BridgeBio crosses over to public markets with $349m
AIG scored an exit as genetic disease and cancer drug developer BridgeBio Pharma floated above its range while increasing the number of shares in its IPO.
test reg